Clinical Trial Update: Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma [NA]

View source ↗

Summary

Clinical trial evaluating Rituximab in combination with Yttrium-90 ibritumomab tiuxetan for recurrent primary central nervous system lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• ibritumomab tiuxetan (ibritumomab tiuxetan)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma | NA | Status: COMPLETED